TONADO

March 31, 2016May 13, 2016

Stiolto Respimat for COPD Granted FDA’s Supplemental NDA Approval

Chronic Bronchitis, COPD, Emphysema, News

The FDA has approved a supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s Stiolto Respimat, which, according to the company, adds data to the product’s label demonstrating improvements in health and quality ... Read more

November 23, 2015November 23, 2015

German Assessment Sees Limits to New COPD Inhalation Therapy

COPD, News

The German Institute for Quality and Efficiency in Health Care (IQWiG) recently published a dossier assessment of the drug combination tiotropium and olodaterol, finding that the therapy showed some added benefit over appropriate comparator ... Read more

May 29, 2015November 9, 2015

FDA Approves Boehringer Ingelheim’s Stiolto Respimat as Maintenance Treatment for Patients With COPD

COPD, News

Boehringer Ingelheim announced that the FDA has approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. The drug was approved for long-term continuation therapy of the obstruction of the airflow in chronic ... Read more

May 21, 2015November 9, 2015

Boehringer’s Drug Combination Therapy For COPD Promotes Lung Function Improvement in Patients

COPD, News

Boehringer Ingelheim Pharmaceuticals, Inc. recently announced new data from the pivotal Phase III TONADO™ 1&2 studies (NCT01431274 and NCT01431287), regarding the efficacy and safety of its investigational product tiotropium/olodaterol delivered via ... Read more